A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States.
Rajiv MallickRashad CarltonJoris Van Stiphout
Published in: PharmacoEconomics - open (2023)
This analysis projects that Hizentra is likely associated with favorable economic benefit compared with IVIG in managing CIDP.